NASDAQ:FLGT • US3596641098
The current stock price of FLGT is 14.77 USD. Today FLGT is up by 0.61%. In the past month the price decreased by -35.7%. In the past year, price decreased by -14.33%.
ChartMill assigns a technical rating of 0 / 10 to FLGT. When comparing the yearly performance of all stocks, FLGT is a bad performer in the overall market: 88.54% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to FLGT. FLGT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
On February 27, 2026 FLGT reported an EPS of 0.16 and a revenue of 83.34M. The company beat EPS expectations (422.88% surprise) and missed revenue expectations (-4.31% surprise).
9 analysts have analysed FLGT and the average price target is 34.34 USD. This implies a price increase of 132.5% is expected in the next year compared to the current price of 14.77.
For the next year, analysts expect an EPS growth of -179.61% and a revenue growth 7.81% for FLGT
Over the last trailing twelve months FLGT reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS decreased by -16.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.54% | ||
| ROE | -3.82% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.5 | 96.777B | ||
| CI | THE CIGNA GROUP | 8.55 | 70.049B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 92.56 | 25.127B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.59 | 22.071B | ||
| LH | LABCORP HOLDINGS INC | 14.65 | 21.795B | ||
| GH | GUARDANT HEALTH INC | N/A | 10.825B | ||
| DVA | DAVITA INC | 10.66 | 10.224B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 27.62 | 7.478B | ||
| CHE | CHEMED CORP | 16.57 | 5.502B | ||
| HIMS | HIMS & HERS HEALTH INC | 45.36 | 5.434B | ||
| RDNT | RADNET INC | 78.04 | 4.626B | ||
| OPCH | OPTION CARE HEALTH INC | 15.36 | 4.598B | ||
| HNGE | HINGE HEALTH INC-A | 23.31 | 3.5B |
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
IPO: 2016-09-28
FULGENT GENETICS INC
4399 Santa Anita Ave
El Monte CALIFORNIA 91780 US
CEO: Ming Hsieh
Employees: 1313
Phone: 13026587581
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
The current stock price of FLGT is 14.77 USD. The price increased by 0.61% in the last trading session.
FLGT does not pay a dividend.
FLGT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
The PE ratio for FULGENT GENETICS INC (FLGT) is 36.02. This is based on the reported non-GAAP earnings per share of 0.41 and the current share price of 14.77 USD.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FLGT.
FULGENT GENETICS INC (FLGT) currently has 1313 employees.